ALTUVOCT® maintained FVIII levels within the normal range or close to normal for most of the week1,4
ALTUVOCT® once a week maintained average levels of FVIII >40 UI/dL for most of the week with an average trough level of 15 IU/dL on day 7.1
AVERAGE HALF-LIFE OF 47 HOURS1
Half-life for patients < 6 years; 38,0 hours. Half-life for patients 6 till < 12 years; 42,4 hours.5-6
† oktokog alfa; Kovaltry och Advate. ‡ rurioktokog alfa pegol; Adynovi.
References
FVIII activity over time and pharmacokinetic variables were additional secondary endpoints in XTEND-1 and XTEND-Kids. ABR was defined as the number of treated bleeding episodes, which are the occurrence of haemorrhage that required administration of ALTUVOCT, measured from the first sign of bleed to ≤72 hours after the last injection to treat the bleeding episode.1,2
*ALTUVOCT sustains FVIII levels in the non-haemophilia range for up to 4 days in adults and adolescents and up to 3 days in children;1–3 †Pharmacokinetic sampling was performed over a period of 3, 5, and 14 days after the administration of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa, respectively.4
ABR, annualised bleed rate; ED, exposure day; FVIII, factor VIII; SD, standard deviation; SHA, severe haemophilia A.
EHL, extended half-life; SHL, standard half-life; FVIII, coagulation factor VIII
References for diagrams of FVIII Activity levels in Adults & Adolescents and Children
1. von Drygalski A et al. N Engl J Med 2023;388:310–8;
2. Malec L et al. N Engl J Med 2024;391:235–46 ;
3. Srivastava A et al. Haemophilia 2020;26:1–158;
4. Lissitchkov T et al. Res Pract Thromb Haemost 2023;7:100176;
References for Half-life infographic
1. von Drygalski A, et al. N Engl J Med 2023;388(4):310–318.
2. Dargaud Y, et al. Haematologica 2024;109(8).
5. Malec L, et al. N Engl J Med 2024;391:235–246.
6. Simoneau J, Weyand A. Haematology 2023;1982):2-3.
7. Lissitchkov T, et al. Res Pract Thromb Haemost 2023;7(4):100176.